Postprandial Fatty Acid Metabolism in the Natural History of Type 2

Status Completed

Clinical Trial Summary

Lipotoxicity-causing fatty acid overexposure and accretion in lean tissues leads to insulin resistance and impaired pancreatic β-cell function - the hallmarks of T2D - contributing to associated complications such as heart failure, kidney failure and microvascular diseases. Proper dietary fatty acid (DFA) storage in white adipose tissue (WAT) is now thought to prevent lean-tissue lipotoxicity. Using novel Positron-Emission Tomography (PET) and stable isotopic tracer methods which were developed in Sherbrooke, the investigator showed that WAT storage of DFA is impaired in people with pre-diabetes or T2D. The investigator also showed that this impairment is associated with greater cardiac DFA uptake, as well as subclinical left-ventricular systolic and diastolic dysfunction. Then, It has been found that modest weight loss in pre-diabetics, after a one-year lifestyle intervention, improved WAT DFA storage, curbed cardiac DFA uptake, and restored associated left-ventricular dysfunction. It has been also found that a 7-day low-saturated fat, low-calorie diet raised insulin sensitivity but did not restore WAT or cardiac DFA metabolism. Whether WAT DFA storage directly impacts cardiac DFA uptake is not known. Importantly, the investigator recently uncovered marked sex-specific differences in WAT DFA metabolism. These may explain, at least in part, sex-related differences in the cardiac DFA uptake, which occurs in pre-diabetes. Higher spillover of WAT DFA into circulating Non-Esterified Fatty Acid (NEFA) appears to be linked in women to greater cardiac DFA uptake, as opposed to direct cardiac chylomicron triglycerides (TG) uptake in men. Here, the investigator will isolate and compare organ-specific fatty acid uptake occurring postprandially from chylomicron-TG vs. NEFA pools, as well as the oxidative vs. non-oxidative intracellular metabolic pathways associated with increased cardiac DFA uptake in pre-diabetic men and women.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02808182
Study type	Interventional
Source	Université de Sherbrooke
Contact
Status	Completed
Phase	N/A
Start date	January 17, 2017
Completion date	May 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05354245` - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)	N/A
Completed	`NCT04088461` - Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine	Phase 4
Completed	`NCT02621060` - Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance	Phase 2
Completed	`NCT01488279` - Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy	N/A
Completed	`NCT01521312` - ACute and Chronic Effects of Saxagliptin	Phase 2
Completed	`NCT01559896` - Egg Protein Hydrolysate and Vascular Function	N/A
Completed	`NCT01030978` - Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program	N/A
Completed	`NCT00573781` - Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism	Phase 2
Terminated	`NCT00846521` - Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity	Phase 4
Completed	`NCT00241072` - Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance	Phase 4
Completed	`NCT00536250` - Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth	N/A
Completed	`NCT02254317` - Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance	N/A
Completed	`NCT03764423` - Health Effects of Salmon Fishmeal in Humans	N/A
Recruiting	`NCT05347030` - Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population	N/A
Active, not recruiting	`NCT04341571` - Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes.	Phase 2
Completed	`NCT02700334` - Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes	Phase 4
Active, not recruiting	`NCT01933529` - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)	Phase 2
Completed	`NCT02135172` - Breaks in Sedentary Time and Glucose Regulation in Women	N/A
Active, not recruiting	`NCT01841229` - Effect of Ginseng on Glycemic Control	N/A
Completed	`NCT02248272` - Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D) — AGL11

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms